Crescent Biopharma Files $500M Universal Shelf, Launches $200M At-The-Market Offering
CBIO sits 96% above its 52-week low of $8.72.
Summary
Crescent Biopharma filed a universal shelf registration for up to $500 million in various securities and simultaneously launched a new $200 million At-The-Market (ATM) offering of ordinary shares.
Key Events · Financing and Capital Events · CBIO
-
Universal Shelf Registration Filed
The company registered a universal shelf offering for up to $500 million in various securities, including ordinary shares, preferred shares, debt securities, warrants, and units. This authorizes future capital raises.
-
New $200M At-The-Market (ATM) Offering Launched
Crescent Biopharma entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $200 million of its ordinary shares from time to time through an ATM program. This is a new program established today, July 1, 2026.
-
Significant Potential Dilution
The $200 million ATM offering, if fully sold at an assumed price of $18.00 per share, would issue 11,111,111 new shares. Based on 27,571,935 shares outstanding as of March 31, 2026, this represents a potential dilution of approximately 40.3% for existing shareholders.
-
Use of Proceeds
Net proceeds from the offering are intended for general corporate purposes, including research and development and working capital.
Analysis · CBIO · Life Sciences
Crescent Biopharma has registered a substantial universal shelf offering of up to $500 million, which includes a new $200 million At-The-Market (ATM) equity program. The ATM program alone represents a significant portion of the company's current market capitalization and could result in over 40% dilution for new investors if fully utilized at the assumed price. This capital raise is intended for general corporate purposes, including research and development and working capital, indicating a need for funds to support ongoing operations and clinical trials. The sheer size of the potential offering suggests a material impact on the company's capital structure and future share price.
At the time of this filing, CBIO was trading at $17.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $470.9M. The 52-week trading range was $8.72 to $27.41. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.